Pink Sheet Podcast: Sharpless' Future, Sharpless On Data Manipulation, and Mylan's Insulin Complete Response Letter
Executive Summary
Pink Sheet reporters discuss the questions about Acting Commissioner Norman Sharpless' future at the US FDA, his comments about the data manipulation scandal, and the complete response letter that is delaying Mylan's follow-on insulin product.
You may also be interested in...
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.
Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director
Nicole Verdun said children could participate in gene therapy clinical trials earlier if the necessary controls are in place.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.